Cargando…
Impact of Dose Delays and Alternative Dosing Regimens on Pertuzumab Pharmacokinetics
PERJETA (pertuzumab), administered with Herceptin (trastuzumab), is used in the treatment of human epidermal growth factor receptor 2‐positive breast cancer. Pertuzumab is currently approved with an initial loading dose of 840 mg, followed by a 420‐mg maintenance dose intravenously every 3 weeks. A...
Autores principales: | Liu, Stephanie N., Lu, Tong, Jin, Jin Y., Li, Chunze, Girish, Sandhya, Melnikov, Fjodor, Badovinac Crnjevic, Tanja, Machackova, Zuzana, Restuccia, Eleonora, Kirschbrown, Whitney P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361934/ https://www.ncbi.nlm.nih.gov/pubmed/33719071 http://dx.doi.org/10.1002/jcph.1855 |
Ejemplares similares
-
Population pharmacokinetic and exploratory exposure–response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study
por: Wang, Bei, et al.
Publicado: (2021) -
Population Pharmacokinetic Modeling and Simulations to Evaluate a Potential Dose Regimen of Testosterone Undecanoate in Hypogonadal Males
por: Pastuszak, Alexander W., et al.
Publicado: (2021) -
Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study
por: Kirschbrown, Whitney P., et al.
Publicado: (2018) -
Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative Colitis
por: Wei, Xiaohui, et al.
Publicado: (2017) -
Model‐Based Approach to Predict Adherence to Protocol During Antiobesity Trials
por: Sharma, Vishnu D., et al.
Publicado: (2017)